Relevant bibliographies by topics / Heart valve disease

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Heart valve disease'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Heart valve disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Heart valve disease"

1

Soler-Soler, J. "VALVE DISEASE: Worldwide perspective of valve disease." Heart 83, no. 6 (June 1, 2000): 721–25. http://dx.doi.org/10.1136/heart.83.6.721.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Iung, B. "VALVE DISEASE: Interface between valve disease and ischaemic heart disease." Heart 84, no. 3 (September 1, 2000): 347–52. http://dx.doi.org/10.1136/heart.84.3.347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Piper, C. "VALVE DISEASE: Prosthetic valve endocarditis." Heart 85, no. 5 (May 1, 2001): 590–93. http://dx.doi.org/10.1136/heart.85.5.590.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Otto, C. M. "VALVE DISEASE: Timing of aortic valve surgery." Heart 84, no. 2 (August 1, 2000): 211–18. http://dx.doi.org/10.1136/heart.84.2.211.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Groves, P. "VALVE DISEASE: Surgery of valve disease: late results and late complications." Heart 86, no. 6 (December 1, 2001): 715–21. http://dx.doi.org/10.1136/heart.86.6.715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yanagawa, Bobby, and Subodh Verma. "Heart valve disease." Current Opinion in Cardiology 31, no. 2 (March 2016): 125–26. http://dx.doi.org/10.1097/hco.0000000000000270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Helms, Adam S., and David S. Bach. "Heart Valve Disease." Primary Care: Clinics in Office Practice 40, no. 1 (March 2013): 91–108. http://dx.doi.org/10.1016/j.pop.2012.11.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vahanian, A. "VALVE DISEASE: Balloon valvuloplasty." Heart 85, no. 2 (February 1, 2001): 223–28. http://dx.doi.org/10.1136/heart.85.2.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Eykyn, S. J. "VALVE DISEASE: Endocarditis: basics." Heart 86, no. 4 (October 1, 2001): 476–80. http://dx.doi.org/10.1136/heart.86.4.476.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pretre, R. "VALVE DISEASE: Cardiac valve surgery in the octogenarian." Heart 83, no. 1 (January 1, 2000): 116–21. http://dx.doi.org/10.1136/heart.83.1.116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Heart valve disease"

1

Peacock, Jacqueline D. "The Role of Sox9 in Heart Valve Development and Disease." Scholarly Repository, 2011. http://scholarlyrepository.miami.edu/oa_dissertations/543.

Full text
Abstract:
Heart valve structures open and close during the cardiac cycle to provide unidirectional blood flow through the heart, critical for efficient cardiovascular function. Valve dysfunction results in either incomplete opening or incomplete closure of the valve. Both types of valve dysfunction decrease efficiency of blood flow, increasing the load on the myocardium and leading to secondary heart disease such as pathological hypertrophy and heart failure. There are currently no effective treatments to prevent or slow the progression of valve disease, and there are no pharmacological treatments for advanced valve disease. Although most valve disease is associated with aging, increasing evidence suggests that valve disease often has origins in development. Congenital valvuloseptal defects affect many newborns, ranging from life-threatening malformations requiring immediate repair to more subtle, often undiagnosed defects that increase susceptibility to valve disease later in life. Therefore, an improved understanding of the mechanisms of heart valve formation and maintenance of adult valves may serve as an important step in improving valve disease treatment options. In this work, the mechanisms of normal valve development and the role of Sox9 in developing and mature valves are further studied. The temporal and spatial expression of extracellular matrix genes and proteins are examined throughout normal murine valve development. Sox9 function in the processes of valve development and valve maintenance is examined using mouse models of conditional Sox9 loss-of-function. Heart valve phenotypes in mice with reduced Sox9 function are examined throughout development and in adult mice with resultant calcific valve disease. The possible causative mechanisms of calcific valve disease in mice with reduced Sox9 function are further investigated by identification of novel possible targets of Sox9 transcriptional regulation. Together these studies improve our understanding of heart valve development, characterize a model of heart valve calcification with genetic etiology, and identify and characterize novel targets of Sox9.
APA, Harvard, Vancouver, ISO, and other styles
2

Sharma, Vishal. "Natriuretic peptides in valvular heart disease." Thesis, University of Edinburgh, 2016. http://hdl.handle.net/1842/23463.

Full text
Abstract:
Plasma natriuretic peptide concentrations rise in response to either atrial or ventricular wall stretch and have been found to be useful in the diagnosis and assessment of patients with congestive cardiac failure. Although previous studies have suggested that plasma natriuretic peptides may offer some prognostic information in patients with valvular heart disease, it is unclear whether concentrations reflect disease severity and how plasma concentrations vary across different valve lesions. The aim of this research was to identify the factors that affect natriuretic peptide releases in valvular heart disease (VHD) and to investigate whether natriuretic peptides can be used in clinical practice to identify those patients who may benefit from early intervention. Plasma brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) concentrations were measured in patients with normal left ventricular (LV) systolic function and isolated VHD (mitral regurgitation, MR, n=33; aortic regurgitation, AR, n=39; aortic stenosis, AS, n=34; mitral stenosis, MS, n=30), and age and sex matched controls (n=39) immediately prior to exercise stress echocardiography. Peptide levels were compared against age and sex matched controls and against markers of severity for each valve lesions and across different valve lesions. Compared to controls, patients with all types of VHD had elevated plasma BNP concentrations [(MR median 35(inter quartile range 23-52), AR 34(22-45), AS 31(22-60), MS 58(34-90); controls 24(16-33) pg/mL; p < 0.01 for all]. LV end diastolic volume index varied by valve lesion; [MR (mean ± standard deviation 77±14), AR (91±28), AS (50±17), MS (43±11), controls (52±13) mL/m2; p < 0.0001]. There were no associations between LV volume and BNP. Left atrial (LA) area index varied [MR (18±4cm2/m2), AR (12±2), AS (11±3), MS (19±6), controls (11±2); p < 0.0001], but correlated with plasma BNP concentrations: MR (r=0.42,p=0.02), MS (r=0.86,p < 0.0001), AR (r=0.53,p=0.001), AS (r=0.52, p=0.002). Higher plasma BNP concentrations were associated with increased pulmonary artery pressure and reduced exercise capacity. Despite adverse cardiac remodelling, 81(60%) patients had a BNP concentration within the normal range. In patients with MS BNP was strongly associated with left atrial area index (r=0.86; p < 0.0001) and a BNP level of greater than 2 times the upper limit of normal identified patients who fulfilled guideline criteria for intervention (Area under the curve (AUC) 0.87 [0.74,0.99], p =0.006) and lower exercise capacity (AUC 0.82 [0.67,0.97]; p=0.004). In AR patients significant remodelling could occur whilst BNP remained within the normal range and in general BNP appeared less useful in assessing disease severity. However raised levels of BNP was associated with more severe AR as assessed by left ventricular outflow tract:AR Jet area ratio (r=0.43 p=0.0007). AR patients with an abnormal BNP had signs of early LV dysfunction on exercise with a lower LV longitudinal strain rate post exercise compared to AR patients with a normal BNP (0.68±0.31 vs. 1.06±0.45 1/sec; p=0.02). In MR patients, higher plasma BNP concentrations were associated with larger left atrial area index (r=0.42, p=0.02), higher pulmonary artery pressure (r=0.53, p=0.002) and a lower exercise time (r=-0.60, p=0.0002). BNP was not associated with any marker of left ventricular size or function in MR. These findings suggest that despite significant LV remodelling, plasma BNP concentrations are often normal in patients with VHD. Consequently, plasma BNP concentrations should be interpreted with caution when assessing patients with VHD. However natriuretic peptide levels offer complementary information to the standard assessment of patients with VHD and an unexplained finding of an elevated BNP in an otherwise asymptomatic patient should prompt further investigation.
APA, Harvard, Vancouver, ISO, and other styles
3

Wallby, Lars. "Signs of inflammation in different types of heart valve disease : The VOCIN study." Doctoral thesis, Linköping : Department of Medical and Health Sciences, Linköping University, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-11330.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tseng, Yuan-Tsan. "Heart valve tissue engineering." Thesis, University of Oxford, 2011. http://ora.ox.ac.uk/objects/uuid:e67c780d-d60f-42e7-9311-dd523f9141b3.

Full text
Abstract:
Since current prosthetic heart valve replacements are costly, cause medical complications, and lack the ability to regenerate, tissue-engineered heart valves are an attractive alternative. These could provide an unlimited supply of immunological-tolerated biological substitutes, which respond to patients' physiological condition and grow with them. Since collagen is a major extra cellular matrix component of the heart valve, it is ideal material for constructing scaffolds. Collagen sources have been shown to influence the manufacturing of collagen scaffolds, and two commercial sources of collagen were obtained from Sigma Aldrich and Devro PLC for comparison. Consistencies between the collagens were shown in the primary and secondary structures of the collagen, while inconsistencies were shown at the tertiary level, when a higher level of natural crosslinking in the Sigma collagen and longer polymer chains in the Devro collagen were observed. These variations were reduced and the consistency increased by introducing crosslinking via dehydrothermal treatment (DHT). Collagen scaffolds produced via freeze-drying (FD) and critical point-drying with cross-linking via DHT or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide /N-hydroxysuccinimide (EDC/NHS) were investigated. All the scaffolds were compatible with mesenchymal stem cells (MSCs) according to the proliferation of the cells and their ability to produce ECM, without differentiating between osteogenic, chondrogenic or endothelial lineages. The FD EDC/NHS scaffold demonstrated the most suitable physical property of all. This result illustrates that FD EDC/NHS crosslinking is the most suitable scaffold investigated as a start for heart valve tissue engineering. To prepare a scaffold with a controlled local, spatial and temporal delivery of growth factor, a composite scaffold comprising poly (lactic-co-glycolic acid) (PLGA) microspheres was developed. This composite scaffold demonstrated the same compatibility to the MSCs as untreated scaffold. However, the PLGA microspheres showed an increase in the deterioration rate of Young's modulus because of the detachment of the microspheres from the scaffold via cellular degradation.
APA, Harvard, Vancouver, ISO, and other styles
5

Hadian, Mojtaba. "Study of collagen structure in canine myxomatous mitral valve disease." Thesis, University of Edinburgh, 2009. http://hdl.handle.net/1842/4383.

Full text
Abstract:
Myxomatous mitral valve disease (MMVD) is the single most common acquired cardiac disease of dogs, and is a disease of significant veterinary importance. It also bears close similarities to mitral valve prolapse in humans and therefore is a disease of emerging comparative interest. Realising the importance of collagen fibres in mitral heart valves and considering the paramount significance of myxomatous mitral valve disease, a better understanding of the pathogenesis of MMVD is essential. Thus, this study was designed to investigate the changes in collagen molecules, including fibril structure, fibril orientation, d-spacing, collagen density, collagen content, thermal stability, and the status of mature and immature crosslinks. A combination of biophysical and biochemical tools such as x-ray diffraction, neutron diffraction, HPLC were utilised in order to fulfil the objectives. Biochemical assay of hydroxyproline revealed a 10% depletion of collagen in mildly affacted (grade I and II) leaflets, while a 20% depletion of fibrillar collagen was revealed by mapping the collagen fibrils onto the anatomy of cardiac leaflets using x-ray data. Differential scanning calorimetry showed that there were no significant differences in the onset temperature of denaturation of collagen between the healthy and affected leaflets. However, in affected areas of leaflets, the enthalpy of denaturation significantly dropped by 20%. In the affected regions, neutron diffraction results showed an increase in the immature reducible cross-links though the low number of the samples can be considered a limiting factor in this regard. However, the HPLC results showed a 25% decrease in the number of mature cross-links. Additionally, the recently introduced imaging technologies to biology and medicine such as differential enhancing imaging (DEI) and coherent anti-Stokes Raman scattering spectroscopy (CARS) were, to the author’s best knowledge, applied for the first time to this disease. In doing so, this thesis furthers our understanding of the pathogenesis of MMVD, especially in relation to the collagen. The thesis provides new findings about MMVD and demonstrates the potential of biophysical tools for studying similar conditions.
APA, Harvard, Vancouver, ISO, and other styles
6

Menciotti, Giulio. "Advanced Echocardiographic Imaging In Dogs With Myxomatous Mitral Valve Disease." Diss., Virginia Tech, 2017. http://hdl.handle.net/10919/77704.

Full text
Abstract:
Myxomatous mitral valve degeneration (MMVD) is the most common canine cardiac disease. In the studies presented in this dissertation, we used advanced echocardiographic techniques to elucidate several aspects of MMVD in dogs. Our hypothesis was that the mitral valve (MV) morphology could have a role in the development of MMVD. First, we tested whether we could use real time three-dimensional transthoracic echocardiography (RT-3DTTE), and an offline software for MV analysis to evaluate canine MV. We described that the technique was feasible and repeatable, we evaluated the morphology of the MV in healthy dogs, and we provided reference values for MV morphologic variables in this species. Then, we used the same technique to compare healthy dogs to dogs affected by MMVD. We found that dogs affected by MMVD have more circular and flatter valve. We then analyzed the MV of healthy Cavalier King Charles Spaniels (CKCSs), given the high predisposition of this breed for MMVD. Our findings indicate that compared to healthy dogs of other breeds, the MV of healthy CKCSs is flatter and has less leaflet tenting, corroborating our hypothesis that an altered MV morphology could represent a predisposing factor for disease development. We also used RT–3DTTE to characterize the area of the regurgitant MV orifice of dogs affected with MMVD, finding that the technique requires further standardization in order to become clinically useful. The elevation of pulmonary venous pressure caused by MMVD can, in some dogs, cause pulmonary arterial hypertension (PH), which is a risk factor associated with worse outcome in dogs with MMVD. Diagnosis of PH in dogs with MMVD is usually made by estimating pulmonary pressure using Doppler echocardiography. We are currently evaluating the accuracy of this technique, compared to invasive measurement of pulmonary pressure. Only preliminary data are presented regarding this study, as the disclosure of the blinding would have infringed the power of the study. Our preliminary results demonstrate that there is only moderate agreement between the two techniques, indicating that caution should be used when deriving the non-invasive estimation of systolic pulmonary pressure in order to make clinical decisions.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
7

Kim, Andrew. "Targeted macrophage depletion is protective against heart valve disease in Marfan syndrome." University of Cincinnati / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1562059861013629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lopez-Alvarez, Jordi. "Evaluation of early indicators of disease progression in dogs with degenerative mitral valve disease." Thesis, Royal Veterinary College (University of London), 2015. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.669194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Weinberg, Eli 1979. "Multiscale simulations of the aortic heart valve : applications in disease and surgery." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/44797.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2008.
Includes bibliographical references (p. 136-148).
This thesis presents mathematical models describing the mechanical behavior of the human aortic heart valve over a range of length and time scales. In the human heart, the valves perform the vital function of controlling the direction of blood flow. Each valve is an intricate mechanical structure, with distinct features and functions at multiple scales. This effort first develops a framework of reference configurations that enables communication between simulations of the different length scales. Three simulations are created within that framework. At the cell scale, the interaction between a single valvular interstitial cell and its surrounding matrix is described. At the tissue scale, a model is created for the valve cusp tissue mechanical behavior, including the multilayered, nonuniform geometry and nonlinear, anisotropic material properties. At the organ scale, a dynamic, three-dimensional model with fluid-structure interaction predicts the motion of the valve, blood, and surrounding tissue. Each simulation is verified against a number of experimental measures. These three simulations together constitute a model for the dynamic, three-dimensional, multiscale mechanical behavior of the healthy human aortic heart valve throughout the cardiac cycle. The model is employed to perform multiscale investigation into the mechanisms of the disease calcific aortic stenosis in three ways. First, the model of the healthy valve is extended to describe disease progression on the decade time scale. Calcification is introduced at the tissue level and the effects on valve function are monitored at the organ level. Second, the role of mechanical deformations in the disease process is examined by comparing multiscale deformations between the normal valve case and a known disease-prone case.
(cont.) Finally, a combined computational and experimental study investigates the role of fluid shear in calcific disease. Shears computed in the organ-scale simulation are applied to endothelial cells in vitro. The cells express disease-related genes in a manner consistent with the region-specific nature of calcific disease, providing evidence for a role of shear in the disease process. The multiscale model presented in this thesis has further utility in investigating function, disease, and therapy of the human aortic valve.
by Eli J. Weinberg.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
10

LaHaye, Stephanie Donna. "Discovering and Modeling Genetic Causes of Congenital Heart Disease." The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492610446228702.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Heart valve disease"

1

Zamorano, Jose, Patrizio Lancellotti, Luc Pierard, and Philippe Pibarot, eds. Heart Valve Disease. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-23104-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Valvular heart disease. Dordrecht: Humana Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

1951-, Al Zaibag Muayed, and Gomez-Duran Carlos, eds. Valvular heart disease. New York: M. Dekker, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Otto, Catherine M. Valvular heart disease. 2nd ed. Philadelphia, PA: Saunders, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Valvular heart disease. 2nd ed. Philadelphia, Pa: W.B. Saunders Co., 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Valvular heart disease. Philadelphia: W.B. Saunders, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

M, Dunn Jeffrey, ed. Cardiac valve disease in children. New York, N.Y: Elsevier, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Acar, Jean. Textbook of acquired heart valve disease. London: ICR, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Acar, Jean. Textbook of acquired heart valve disease. London: ICR, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Giamberti, Alessandro, and Massimo Chessa, eds. The Tricuspid Valve in Congenital Heart Disease. Milano: Springer Milan, 2014. http://dx.doi.org/10.1007/978-88-470-5400-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Heart valve disease"

1

John, Ranjit, and Kenneth Liao. "Heart Valve Disease." In Heart Valves, 121–58. Boston, MA: Springer US, 2013. http://dx.doi.org/10.1007/978-1-4614-6144-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Aberle, Corinne M., Chrisita L. Powlett, and Jennifer R. Cozart. "Valve Prosthesis." In Valvular Heart Disease, 223–35. London: Springer London, 2019. http://dx.doi.org/10.1007/978-1-4471-2840-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

John, Ranjit, and Kenneth K. Liao. "Heart Valve Disease." In Handbook of Cardiac Anatomy, Physiology, and Devices, 527–49. Totowa, NJ: Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-372-5_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gallegos, Robert P., and R. Morton Bolman. "Heart Valve Disease." In Handbook of Cardiac Anatomy, Physiology, and Devices, 385–404. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-835-9_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Harvey, Laura, Kenneth K. Liao, and Ranjit John. "Heart Valve Disease." In Handbook of Cardiac Anatomy, Physiology, and Devices, 635–57. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-19464-6_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kondapalli, Lavanya, Amber Berning, Suparna C. Clasen, and Rhonda Miyasaka. "Carcinoid Heart Disease." In Tricuspid Valve Disease, 111–21. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92046-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kondapalli, Lavanya, Amber Berning, Suparna C. Clasen, and Rhonda Miyasaka. "Carcinoid Heart Disease." In Tricuspid Valve Disease, 111–21. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-92046-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Unger, Philippe, and Mauro Pepi. "Multiple Valve Disease." In Heart Valve Disease, 193–205. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23104-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hahn, Rebecca T. "Tricuspid Valve Disease." In Heart Valve Disease, 127–45. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-23104-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Corno, Antonio F. "Mitral valve disease." In Congenital Heart Defects, 117–31. Heidelberg: Steinkopff, 2004. http://dx.doi.org/10.1007/978-3-7985-1934-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Heart valve disease"

1

Suboh, Mohd Zubir, Muhyi Yaakop, Mohd Syazwan Md Yid, Mohd Azlan Abu, and Imran Mohammad Sofi. "Heart valve disease screening system — PC based." In 2017 International Conference on Engineering Technology and Technopreneurship (ICE2T). IEEE, 2017. http://dx.doi.org/10.1109/ice2t.2017.8215968.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zadeh, Parnian Boloori, Hamid N.-Hashemi, Scott C. Corbett, and Ahmet U. Coskun. "Calcification of Trileaflet Polyurethane Heart Valve." In ASME 2010 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2010. http://dx.doi.org/10.1115/sbc2010-19486.

Full text
Abstract:
Heart valve disease is a common type of cardiac disease that causes a large number of mortalities worldwide. Patients with severe heart valve problems are required to undergo heart valve replacement surgeries. Mechanical and bioprosthetic heart valves are the current available prostheses for patients in need of a heart valve replacement surgery. Mechanical heart valves are susceptible to thromboembolism and thrombosis and bioprosthetic valves have a limited life-span because of leaflet wear and calcification. Different polyurethane valves were suggested as an alternative material. However, prior results indicated that tested polyurethanes failed due to calcification. The mechanism for polyurethane calcification is not yet completely understood. Kou Imachi et al. [2], suggested that the calcification is due to entrapment of blood proteins and/or phospholipids in microgaps in the polymer and subsequent attraction of Ca ion, leading to formation of calcium phosphate (Ca3(PO4)2). Bisphosphonates (BP), which are considered to enhance the calcification resistance of polymers once covalently bonded to the material, indicated promising results in some studies. Focus of the present study is the trileaflet polyurethane valve, originally developed in the design of the AbioCor® replacement heart, and has demonstrated excellent durability and hemocompatibility in clinical evaluation. Over the past three years, this valve has been modified and its potential as a replacement valve have been studied [1]. Valve hemodynamic analysis showed that it is comparable to bioprosthetic valve in terms of fluid flow, pressure drop and regurgitation [1]. In order to ensure the suitability of the trileaflet polyurethane valve as a replacement valve its fatigue and calcification resistance are studied. The purpose of this paper is to simulate calcification of trileaflet polyurethane valves in an in vitro accelerated test and compare that with that of tissue valves. Furthermore the effect of bisphosphonate modified polyurethane on calcification is studied.
APA, Harvard, Vancouver, ISO, and other styles
3

Xiao, Min, Annie Bailey, and Olga Pierrakos. "In-Vitro Modeling of Heart Failure in the Presence of a Prosthetic Heart Valve Using Particle Image Velocimetry." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53788.

Full text
Abstract:
It is well-known that cardiovascular disease, affecting millions of people, is the number one killer in the US and worldwide. Current trends indicate that cardiovascular disease (CVD) will claim approximately 20 million victims in 2020 as the leading cause of death worldwide and will be responsible for over a billion deaths between 2000 and 2050 [1]. According to the American Heart Association, one in three American adults have one or more types of heart disease. Economically, the total and indirect costs due to cardiovascular diseases in 2009 were estimated at $475.3 billion. The spectrum of cardiac disease encompasses a broad range of disorders, varying from myocardial ischemia, valvular disease, diastolic dysfunction, congestive heart failure (which is projected to affect 20 million people by 2020), etc. Most of these disorders initiate and are associated to the left side of the heart, which is the workhorse and also the focus of our research herein.
APA, Harvard, Vancouver, ISO, and other styles
4

Schoephoerster, Richard T., Siobhain Gallocher, Leonard Pinchuk, and Vladimir A. Kasyanov. "A Novel Trileaflet Synthetic Heart Valve." In ASME 2001 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2001. http://dx.doi.org/10.1115/imece2001/bed-23112.

Full text
Abstract:
Abstract Heart valve prostheses have been used successfully since 1960 and generally result in improvement in the longevity and symptomatology of patients with valvular heart disease. However, NIH’s Working Group on Heart Valves reports that 10-year mortality rates still range from 30–55%, and that improvements in valve design are required to minimize thrombotic potential and structural degradation and to improve morbidity and mortality outcomes.
APA, Harvard, Vancouver, ISO, and other styles
5

Dubey, Shivansh, Raghuvendra Pratap Tripathi, Malay Kishore Dutta, Jan Dorazil, and Petr Kriz. "Early Detection of Heart Valve Disease Employing Multiclass Classifier." In 2019 11th International Congress on Ultra Modern Telecommunications and Control Systems and Workshops (ICUMT). IEEE, 2019. http://dx.doi.org/10.1109/icumt48472.2019.8970870.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Claiborne, Thomas E., Michalis Xenos, Jawaad Sheriff, Dinesh Peter, Yared Alemu, Yasushi Kato, Leonard Pinchuk, Shmuel Einav, Jolyon Jesty, and Danny Bluestein. "Development and Optimization of a Novel Polymeric Prosthetic Heart Valve Using the Device Thrombogenicity Emulation (DTE) Methodology." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80186.

Full text
Abstract:
Calcific aortic valve disease (CAVD) is the most common and life threatening form of valvular heart disease, characterized by stenosis and regurgitation, which is currently treated at the symptomatic end-stages via open-heart surgical replacement of the diseased valve with typically either a xenograft tissue valve or mechanical heart valve. These options offer the clinician a choice between structural valve deterioration and anticoagulant therapy respectively, effectively replacing one disease with another [1]. Polymeric heart valves (PHV) offer the promise of reducing or eliminating these complications [2] and may be efficacious for patients who cannot tolerate cardiothoracic surgery by using instead transcatheter valve implantation (TAVI) [3], where there is evidence that tissue valves are damaged during implantation [4], and in pulsatile circulatory support devices such as the SynCardia Total Artificial Heart. But development of PHVs has been slow due to the lack of sufficiently durable and biocompatible formulations.
APA, Harvard, Vancouver, ISO, and other styles
7

Stepan, Lenka, Daniel Levi, and Gregory Carman. "A Thin Film Nitinol Heart Valve." In ASME 2004 International Mechanical Engineering Congress and Exposition. ASMEDC, 2004. http://dx.doi.org/10.1115/imece2004-60850.

Full text
Abstract:
In order to create a less thrombogenic heart valve with improved longevity, a prosthetic heart valve was developed using thin film nitinol (NiTi). A “butterfly” thin film NiTi valve was constructed using a single, elliptical piece of thin film NiTi and a scaffold made from Teflon tubing and NiTi wire. Flow tests and pressure readings across the valve were performed in vitro in a pulsatile flow loop. Biocorrosion experiments were conducted on untreated and passivated thin film nitinol. To determine the material’s in vivo biocompatibility, thin film nitinol was implanted in a pig using a stent covered with thin film NiTi. Flow rates and pressure tracings across the valve were comparable to those through a commercially available 19 mm Perimount Edwards tissue valve. No signs of corrosion were present on samples of thin film nitinol after immersion in Hank’s solution for 1 month. Finally, organs and tissue samples explanted from the pig 17 days after thin film NiTi implantation appeared without disease, and the thin film nitinol itself was without thrombus formation or endothelialization. Although long term testing will be needed, thin film NiTi may be very well suited for use in artificial heart valves.
APA, Harvard, Vancouver, ISO, and other styles
8

Gogarty, Michael B., and Lakshmi P. Dasi. "In Vitro Beating Heart Simulator for Minimally Invasive Heart Valve Therapy Research." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80743.

Full text
Abstract:
Heart disease is the number one cause of death today with aortic valve stenosis (AVS) being a major contributor to the mortality rate1. Because of the invasive nature of Aortic Valve Resection (AVR), the typical treatment for AVS, between 30–60% of patients affected by severe aortic stenosis cannot be treated surgically, usually due to age and advanced comorbidities. Qualifying individuals must undergo extensive rehabilitation and of those who qualify 4.3% to 25% do not survive the first year following the procedure3,4.
APA, Harvard, Vancouver, ISO, and other styles
9

Mesihović-Dinarević, Senka. "WHAT IS NEW IN CARDIOVASCULAR MEDICINE?" In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.03.

Full text
Abstract:
The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating in adult cardiovascular medicine as well as in paediatric cardiology medicine. Cardiovascular medicine is an area of clinical practice with a continually rapid expansion of knowledge, guidelines, best practices and new technology. Cardiovascular diseases are the leading cause of mortality in the world and cause major costs for the health sector and economy. Primary care clinicians are challenged to optimally manage a multitude of diseases including congestive heart failure, coronary artery disease, valvular diseases, arrhythmias, lipid disorders, and hypertension. Multimodality imaging techniques are being used more frequently as their utility is better appreciated. Echocardiography has been the mainstay approach, cardiac computerized tomography and magnetic resonance imaging provide a good imaging alternative for patients with multiple complex surgeries. 3D printing has seen a rapid growth in use for planning treatments for patients with congenital heart disease. Simulation using 3D models is emerging as a fundamental resource for teaching procedural techniques and a new standard of care. Artificial intelligence holds the greatest potential for revolutionizing medicine. Innovative technologies in the world of cardiovascular health are expanding every day: wearable computing technologies, bioresorbable stents, leadless pacemaker, valve-in-valve procedure, protein patch for heart muscle growth and others. As a part of lifelong learning process for all professionals in cardiovascular medicine, the imperative is to have continuity of reviewing novelties, with results data from numerous researches in order to treat patient according to best practices and evidence-based medicine.
APA, Harvard, Vancouver, ISO, and other styles
10

Dolensky, Joseph R., Lauren D. C. Casa, and Ajit P. Yoganathan. "The Effect of Pulmonary Hypertension on Tricuspid Valve Coaptation in Normal and Pathologic Valve Geometries: An In Vitro Study." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80184.

Full text
Abstract:
Pulmonary hypertension (PHTN) is a pathological condition defined as a mean pulmonary artery pressure (mPAP) greater than 25 mmHg. PHTN can result from a number of lung and heart pathologies, including abnormalities of the pulmonary vasculature, left heart disease, chronic lung disease, and chronic thrombotic disease [1]. Regardless of the cause, the increased afterload on the right heart results in right ventricle (RV) hypertrophy and dilatation and tricuspid regurgitation (TR) [2]. RV dilatation is thought to result in the displacement of the tricuspid valve (TV) papillary muscles (PM) and dilatation of the TV annulus, negatively impacting TV function.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Heart valve disease"

1

Aleksandrov, A. V., L. N. Shilova, I. Yu Alekhina, N. V. Aleksandrova, N. V. Nikitina, and E. V. Benedickaya. COMBINED USE OF IMMUNOLOGICAL AND ULTRASOUND METHODS OF ESTIMATION OF VALVE HEART STATUS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. Планета, 2018. http://dx.doi.org/10.18411/978-5-907109-24-7-2018-xxxv-14-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

AlBakri, Aref, Auswaf Ahsan, Manoj Vengal, KR Ashir, Abdul Majeed, and Hanan Siddiq. Antibiotic Prophylaxis before Invasive Dental Procedures for Patients at High-Risk of Infective Endocarditis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0011.

Full text
Abstract:
Review question / Objective: The aim of the present systematic review and meta-analysis is to determine whether there is a genuine clinical need for Antibiotic Prophylaxis(AP) for the prevention of Infective Endocarditis(IE) in high-risk individuals (particularly those with demonstrable structural heart diseases or valve surgery) undergoing invasive dental procedures. Information sources: PubMed, Science Direct, British Dental Journal and Cochrane Register of Controlled Trials. Search terms used included various combinations of the following subject headings and title or abstract keywords – prophylactic antibiotics, antibiotic prophylaxis, antimicrobial, dentist, extraction, implant, infective endocarditis, or bacterial endocarditis.
APA, Harvard, Vancouver, ISO, and other styles
3

Shalganov, Tchavdar, Milko Stoyanov, and Vassil Traykov. Outcomes following catheter ablation for ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter-defibrillator: protocol for an updated systematic review and meta-analysis of randomized studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0080.

Full text
Abstract:
Review question / Objective: Does catheter ablation for scar-related monomorphic ventricular tachycardia improve outcomes (defined as any appropriate ICD therapy, appropriate ICD shocks, all-cause mortality, VT storm, cardiovascular mortality, cardiovascular hospitalizations, complications) in adult patients with ischemic or non-ischemic cardiomyopathy and implantable cardioverter-defibrillator? Condition being studied: Ventricular tachycardia in patients with structural heart disease is usually an arrhythmia using the myocardial scar as a substrate for reentry. It poses a risk of syncope and sudden cardiac death, especially in patients with reduced ejection fraction. Most antiarrhythmic drugs are of little value and their use is restricted in patients with LV systolic dysfunction. Catheter ablation is a viable option for the treatment of ventricular tachycardia. In patients with previous myocardial infarction the arrhythmogenic scar is located most frequently subendocardially and is readily accessible using endocardial approach, while in non-ischemic cardiomyopathy the scar is frequently located in the midmyocardial or subepicardial layers. This is the reason endocardial catheter ablation to be less effective in those patients and to more often necessitate epicardial approach.
APA, Harvard, Vancouver, ISO, and other styles
4

Tang, Jiqin, Gong Zhang, Jinxiao Xing, Ying Yu, and Tao Han. Network Meta-analysis of Heat-clearing and Detoxifying Oral Liquid of Chinese Medicines in Treatment of Children’s Hand-foot-mouth Disease：a protocol for systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0032.

Full text
Abstract:
Review question / Objective: The type of study was clinical randomized controlled trial (RCT). The object of study is the patients with HFMD. There is no limit to gender and race. In the case of clear diagnosis standard, curative effect judgment standard and consistent baseline treatment, the experimental group was treated with pure oral liquid of traditional Chinese medicine(A: Fuganlin oral liquid, B: huangzhihua oral liquid, C: Lanqin oral liquid, D: antiviral oral liquid, E: Huangqin oral liquid, F: Pudilan oral liquid, G: Shuanghuanglian oral liquid.)and the control group was treated with ribavirin or any oral liquid of traditional Chinese medicine. The data were extracted by two researchers independently, cross checked and reviewed according to the pre-determined tables. The data extraction content is (1) Basic information (including the first author, published journal and year, research topic). (2) Relevant information (including number of cases, total number of cases, gender, age, intervention measures, course of treatment of the experimental group and the control group in the literature). (3) Design type and quality evaluation information of the included literature. (4) Outcome measures (effective rate, healing time of oral ulcer, regression time of hand and foot rash, regression time of fever, adverse reactions.). The seven traditional Chinese medicine oral liquids are comparable in clinical practice, but their actual clinical efficacy is lack of evidence-based basis. Therefore, the purpose of this study is to use the network meta-analysis method to integrate the clinical relevant evidence of direct and indirect comparative relationship, to make quantitative comprehensive statistical analysis and sequencing of different oral liquid of traditional Chinese medicine with the same evidence body for the treatment of the disease, and then to explore the advantages and disadvantages of the efficacy and safety of different oral liquid of traditional Chinese medicine to get the best treatment plan, so as to provide reference value and evidence-based medicine evidence for clinical optimization of drug selection. Condition being studied: Hand foot mouth disease (HFMD) is a common infectious disease in pediatrics caused by a variety of enteroviruses. Its clinical manifestations are mainly characterized by persistent fever, hand foot rash, oral herpes, ulcers, etc. Because it is often found in preschool children, its immune system development is not perfect, so it is very vulnerable to infection by pathogens and epidemic diseases, resulting in rapid progress of the disease. A few patients will also have neurogenic pulmonary edema Meningitis, myocarditis and other serious complications even lead to death, so effectively improve the cure rate, shorten the course of disease, prevent the deterioration of the disease as the focus of the study. In recent years, traditional Chinese medicine has played an important role in the research of antiviral treatment. Many clinical practices have confirmed that oral liquid of traditional Chinese medicine can effectively play the role of antiviral and improve the body's immunity.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Heart valve disease' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography